{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-25-000003","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.931846+00:00","generated_at":"2026-05-26T23:13:34.959228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance","bullets":["Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).","GAAP EPS $0.58; adjusted EPS $0.59; full-year sales from continuing ops $5.5B.","2025 guidance reaffirmed: constant currency sales growth 8-10%, adjusted EPS $2.40-$2.50.","Expect mid-year FDA approval for asymptomatic TAVR; presented EARLY TAVR and TRISCEND II trials.","Cash $3.0B; debt $600M; adjusted gross margin 79.0%."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-25-000003","json":"https://secwatch.observer/filing/0001099800-25-000003.json","markdown":"https://secwatch.observer/filing/0001099800-25-000003.md","text":"https://secwatch.observer/filing/0001099800-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/0001099800-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980025000003/ew-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:13:34.959228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}